Outlook Therapeutics Inc [NASDAQ: OTLK] loss -1.39% or -0.12 points to close at $8.51 with a heavy trading volume of 827569 shares. The company report on March 22, 2024 at 7:35 AM that Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a
Outlook Therapeutics Inc [NASDAQ: OTLK] gained 22.59% or 1.59 points to close at $8.63 with a heavy trading volume of 20992691 shares. The company report on March 22, 2024 at 7:35 AM that Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a
Outlook Therapeutics Inc [NASDAQ: OTLK] price plunged by -10.57 percent to reach at -$0.04. The company report on March 12, 2024 at 8:05 AM that Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split. The Company’s common stock will begin trading on a reverse
Outlook Therapeutics Inc [NASDAQ: OTLK] gained 15.35% or 0.06 points to close at $0.48 with a heavy trading volume of 5135733 shares. The company report on February 14, 2024 at 8:05 AM that Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and
Outlook Therapeutics Inc [NASDAQ: OTLK] price surged by 6.61 percent to reach at $0.03. The company report on January 31, 2024 at 8:05 AM that Outlook Therapeutics® Doses First Subject in NORSE EIGHT. NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA)
© 2024, Powered by Smart TechOne
